NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3027% below fair value
$11.83+0.11 (+0.94%)
Close on Nov 13, 2026Market cap $1.38BP/E –Yield –
NovoCure ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
NovoCure's ebitda for the twelve months ending Sep 30, 2026 was -$107.48M. For fiscal 2025 it was -$139.15M. The highest annual figure on record is $39.55M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$139.15M | – |
| FY2024 | Dec 31, 2024 | -$159.26M | – |
| FY2023 | Dec 31, 2023 | -$221.90M | – |
| FY2022 | Dec 31, 2022 | -$78.90M | – |
| FY2021 | Dec 31, 2021 | -$34.08M | -186.2% |
| FY2020 | Dec 31, 2020 | $39.55M | +424.1% |
| FY2019 | Dec 31, 2019 | $7.55M | – |
| FY2018 | Dec 31, 2018 | -$24.67M | – |
| FY2017 | Dec 31, 2017 | -$31.65M | – |
| FY2016 | Dec 31, 2016 | -$109.67M | – |
| FY2015 | Dec 31, 2015 | -$100.84M | – |
| FY2014 | Dec 31, 2014 | -$78.19M | – |
| FY2013 | Dec 31, 2013 | -$63.24M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.76M | – |
| Q2 FY2026 | Jun 30, 2026 | -$6.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$63.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$36.18M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$36.08M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$60.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.63M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.72M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$48.99M | – |
| Q3 FY2023 | Sep 30, 2023 | -$55.44M | – |
| Q2 FY2023 | Jun 30, 2023 | -$59.94M | – |
| Q1 FY2023 | Mar 31, 2023 | -$57.53M | -3288.9% |
| Q4 FY2022 | Dec 31, 2022 | -$40.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.47M | – |
| Q1 FY2022 | Mar 31, 2022 | $1.80M | -20.9% |
| Q4 FY2021 | Dec 31, 2021 | -$20.73M | -242.3% |
| Q3 FY2021 | Sep 30, 2021 | -$5.82M | -133.8% |
| Q2 FY2021 | Jun 30, 2021 | -$9.82M | -205.9% |
| Q1 FY2021 | Mar 31, 2021 | $2.28M | – |
| Q4 FY2020 | Dec 31, 2020 | $14.57M | +455.9% |
| Q3 FY2020 | Sep 30, 2020 | $17.21M | +197.4% |
| Q2 FY2020 | Jun 30, 2020 | $9.27M | +178.5% |
| Q1 FY2020 | Mar 31, 2020 | -$1.49M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.62M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.79M | – |
| Q2 FY2019 | Jun 30, 2019 | $3.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.19M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.46M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.94M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.80M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.47M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.35M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.87M | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.72M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.71M | – |
| Q4 FY2016 | Dec 31, 2016 | -$16.29M | – |
See a number that looks wrong?